|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:doxorubicin
|
|
gptkbp:administeredBy
|
sterile solution
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:ATCCode
|
L01DB01
|
|
gptkbp:brand
|
liposomal doxorubicin
|
|
gptkbp:CASNumber
|
23214-92-8
|
|
gptkbp:chemicalFormula
|
C27H29NO11
|
|
gptkbp:color
|
red
|
|
gptkbp:contraindication
|
severe myelosuppression
hypersensitivity to doxorubicin
|
|
gptkbp:drugClass
|
gptkb:anthracycline_antibiotic
|
|
gptkbp:form
|
pegylated liposomal
|
|
gptkbp:halfLife
|
55 hours
|
|
gptkbp:indication
|
gptkb:cancer
gptkb:AIDS-related_Kaposi's_sarcoma
multiple myeloma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:mechanismOfAction
|
DNA intercalation
topoisomerase II inhibition
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
alopecia
neutropenia
stomatitis
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:tradeNameInEurope
|
Caelyx
|
|
gptkbp:bfsParent
|
gptkb:doxorubicin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Doxil
|